IP Library › Granted Patent US 9,974,854
Granted Patent B2
US 9,974,854 · App. 14/736,897 · Granted May 22, 2018

Synthetic conjugate of CpG DNA and T-help/CTL peptide

Inventor: Don J. Diamond (Glendora, CA)
Assignee: City of Hope
A61K39/39A61K39/21A61K39/385C07K14/005C12N7/00A61K2039/55516A61K2039/55561A61K2039/605A61K2039/6025C07K2319/00C12N2740/16022C12N2740/16034C12N2740/16122
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,974,854
App. No.
14/736,897
Granted
May 22, 2018
Kind
B2
Abstract

Highly effective vaccine compositions are constructed according to the methods of this invention. The methods are amenable to use with any peptidic antigen sequence and involve covalent attachment of an immunostimulatory nucleotide sequence to an antigenic peptide sequence. Preferred antigenic peptides are fusion peptides made up of one or more CTL epitope peptides in sequence fused to a T helper peptide.

Claims (10)

1. A method of increasing the effectiveness of an antigenic peptide CTL epitope vaccine component which comprises conjugating said antigenic peptide CTL epitope to a DNA oligomer, wherein said peptide is selected from the group consisting of SEQ ID NOs:1-4.

2. The method of claim 1 , wherein said DNA oligomer comprises a CpG sequence.

3. The method of claim 2 , wherein said DNA oligomer is a phosphodiester CpG DNA.

4. The method of claim 2 , wherein said DNA oligomer is a fully phosphorothioated backbone CpG DNA.

5. The method of claim 1 , wherein said DNA oligomer comprises about 8 to about 300 nucleotide bases.

6. The method of claim 5 , wherein said DNA oligomer comprises about 15 to about 100 nucleotide bases.

7. The method of claim 5 , wherein said DNA oligomer comprises about 20 to about 25 nucleotide bases.

8. The method of claim 1 , wherein said antigenic CTL peptide is a fusion peptide comprising a T-help epitope and said CTL peptide.

9. The method of claim 8 , wherein said T-help epitope is SEQ ID NO:12.

10. The method of claim 1 , wherein said antigenic peptide is synthetic.

Continuity (3)
Division 11008958 · Dec 13, 2004
Provisional Application 60528706 · Dec 12, 2003
Related Publication 20160000906A1 · Jan 7, 2016